克拉斯
癌症研究
突变
计算生物学
癌症
药物发现
化学
药理学
生物
生物信息学
基因
遗传学
作者
Xingping Zhou,Yang Ji,Jinming Zhou
出处
期刊:Molecules
[MDPI AG]
日期:2023-04-21
卷期号:28 (8): 3615-3615
被引量:4
标识
DOI:10.3390/molecules28083615
摘要
KRAS gene mutation is widespread in tumors and plays an important role in various malignancies. Targeting KRAS mutations is regarded as the “holy grail” of targeted cancer therapies. Recently, multiple strategies, including covalent binding strategy, targeted protein degradation strategy, targeting protein and protein interaction strategy, salt bridge strategy, and multivalent strategy, have been adopted to develop KRAS direct inhibitors for anti-cancer therapy. Various KRAS-directed inhibitors have been developed, including the FDA-approved drugs sotorasib and adagrasib, KRAS-G12D inhibitor MRTX1133, and KRAS-G12V inhibitor JAB-23000, etc. The different strategies greatly promote the development of KRAS inhibitors. Herein, the strategies are summarized, which would shed light on the drug discovery for both KRAS and other “undruggable” targets.
科研通智能强力驱动
Strongly Powered by AbleSci AI